Double trouble for Novartis as DM1, CV phase IIIs crash
Novartis AG was hobbled by a pair of phase III trial failures, as delpacibart etedesiran fell short in…
Roche nabs Simcere’s preclinical trispecific TCE in $1.53B deal
To read the full article sign up for free or sign in. Sep. 8, 2026 By Marian (YoonJee)…
Roche, Eli Lilly secure FDA clearance for Alzheimer’s blood-based test
Roche Holding AG and Eli Lilly and Co. received U.S. FDA clearance for the Elecsys Phospho-Tau (217P) Plasma…
Hanmi that CV MoA: Roche lured to $2.3B metabolic pact
A mechanism of action with a mixed history but signs of promise piqued the interest of Roche AG’s…
Roche nabs Simcere’s preclinical trispecific TCE in $1.53B deal
To read the full article sign up for free or sign in. Sep. 2, 2026 By Marian (YoonJee)…
Novartis taps Alteogen’s ALT-B4 for SC drug delivery in $3B deal
Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous…
Dualitybio’s ADC efforts draw Roche in potential $1B deal
Dualitybio Inc. is getting $45 million up front in a deal with Roche AG’s Genentech unit that could…
Dualitybio’s ADC efforts draw Roche in potential $1B deal
Dualitybio Inc. is getting $45 million up front in a deal with Roche AG’s Genentech unit that could…
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
Cancer Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug…
Novartis to pay $1.5B for Myricx Bio and its novel ADC payloads
Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate…
Roche launches Axelios 1 sequencing platform to rival Illumina
Roche Holding AG is looking to take a share of Illumina Inc.’s dominance in the gene sequencing market…
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to…